MedPath

UCSF Performs World's First OnQ Prostate-Assisted Robotic HIFU Procedure

• Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.

• UCLA researchers found that early radiation therapy side effects in prostate cancer patients may indicate higher risks of serious long-term urinary and bowel complications.

• Vanderbilt researchers discovered that the inherited mutated WNT9B gene, crucial in embryonic prostate development, increases adult prostate cancer risk.

In a groundbreaking development for prostate cancer treatment, the University of California, San Francisco (UCSF) Prostate Center has successfully completed the world's first OnQ Prostate-assisted Focal One Robotic HIFU procedure. This milestone achievement represents a collaboration between Cortechs.ai and EDAP TMS SA, marking a significant advance in precision-guided prostate interventions.

Early Side Effects May Predict Long-term Complications

A significant study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has revealed important findings for prostate cancer patients undergoing radiation therapy. The research indicates that patients who experience side effects early in their radiation treatment course may have an elevated risk of developing more serious long-term urinary and bowel health issues. This insight could prove valuable for treatment planning and patient monitoring.

Genetic Link to Prostate Cancer Risk Identified

Researchers at Vanderbilt University Medical Center have made a crucial discovery regarding prostate cancer risk factors. Their study, published in JCO Precision Oncology, demonstrates that the WNT9B gene, when mutated, increases the risk of developing prostate cancer in adults. This gene, which plays a normal role in embryonic prostate development, provides new insights into the genetic basis of prostate cancer and potential therapeutic targets.

Advances in Melanoma Treatment Research

In parallel developments in cancer research, The Wistar Institute's team, led by Jessie Villanueva, has identified a promising new approach for treating resistant melanoma. Their research, published in Science Translational Medicine, focuses on inhibiting the S6K2 gene, potentially offering new hope for patients with treatment-resistant forms of the disease.

Remembering Dr. Felix Y. Feng

The oncology community mourns the loss of Dr. Felix Y. Feng, who passed away on December 10, 2024, at the age of 48. As the former NRG Oncology Genitourinary Cancer Committee chair and RTOG Foundation member, Dr. Feng made significant contributions to genitourinary cancer research, leading 13 research protocols for NRG and RTOG. His appointment as committee chair in 2018 followed the legacy of his mentor, Dr. Howard Sandler, marking a distinguished career dedicated to advancing cancer treatment.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

BREAKWATER Trial: Braftovi-Erbitux Plus Chemotherapy Shows Promise in BRAF V600E Metastatic Colorectal Cancer

Phase III BREAKWATER trial demonstrates efficacy of first-line combination therapy using Braftovi, Erbitux, and mFOLFOX6 chemotherapy in BRAF V600E mutated metastatic colorectal cancer patients.
The study, led by MD Anderson Cancer Center researchers, represents a significant advancement in targeted therapy approaches for this specific genetic mutation in colorectal cancer.

MD Anderson Reports Breakthrough in Metastatic Prostate Cancer Treatment with Targeted Therapy

New research from MD Anderson's X-Met consortium demonstrates metastasis-directed therapy improves survival rates to 92% at three years compared to 86% with standard care in oligometastatic prostate cancer patients.
A Phase I trial shows promising results for Datopotamab deruxtecan (Dato-DXd) in advanced urothelial cancer, achieving a 25% objective response rate with manageable safety profile.

Pfizer to Present Landmark Survival Data for Cancer Therapies at ASCO GU 2025 Symposium

Pfizer will showcase over 20 abstracts at ASCO GU 2025, including pivotal Phase 3 TALAPRO-2 trial results demonstrating significant overall survival benefits for TALZENNA-XTANDI combination in prostate cancer.
Updated analysis from Phase 3 EV-302 trial confirms sustained survival advantage of PADCEV with pembrolizumab in advanced urothelial cancer, reinforcing its position as a first-line treatment standard.

SYNC-T SV-102 Shows Promising Response in Metastatic Castration-Resistant Prostate Cancer

SYNC-T SV-102, a multi-target immunotherapy, demonstrated an 85% objective response rate in patients with metastatic castration-resistant prostate cancer (CRPC).
The LEGION-100 trial combines cryoablation with intra-tumoral immunotherapy to stimulate the immune system against solid tumors.

Trastuzumab Deruxtecan Shows Promise in HER2-Expressing Metastatic Prostate Cancer: A Case Study

A case study reports a 57% reduction in tumor volume in a metastatic prostate cancer patient treated with trastuzumab deruxtecan (T-DXd).
The patient, who had stage four metastatic prostate cancer and failed multiple lines of therapy, showed significant improvement after T-DXd treatment.

Enzalutamide and Talazoparib Combination Therapy Improves Survival in Late-Stage Prostate Cancer

A novel combination therapy of enzalutamide and talazoparib shows a statistically significant increase in overall survival rates for patients with late-stage prostate cancer.
The TALAPRO-2 trial, a global study led by Huntsman Cancer Institute, demonstrated the efficacy of the combination in improving outcomes for metastatic castration-resistant prostate cancer.

TYRA-300 Shows Promise in Treating Metastatic Bladder Cancer with FGFR3 Alterations

TYRA-300, a selective FGFR3 inhibitor, demonstrates promising antitumor activity in patients with metastatic urothelial cancer harboring FGFR3 alterations, with a 54.5% partial response rate at doses of 90 mg or higher.
The SURF301 trial's early results indicate that TYRA-300 is well-tolerated, with fewer of the adverse effects commonly associated with pan-FGFR inhibitors, offering a potentially improved safety profile.

Talzenna-Xtandi Combo Improves Overall Survival in mCRPC, Regardless of HRR Mutation Status

Pfizer's Talzenna plus Xtandi shows statistically significant and clinically meaningful improvement in overall survival (OS) for mCRPC patients.
The OS benefit was observed in both all-comers and HRR gene-mutated subgroups in the Phase III TALAPRO-2 trial.

TYRA-300: Novel FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer and Achondroplasia

TYRA-300 is a novel, orally available, and highly selective inhibitor of FGFR3, designed to minimize off-target toxicities associated with pan-FGFR inhibitors.
Phase 1 clinical trials are underway, evaluating TYRA-300 in patients with urothelial cancers and solid tumors harboring FGFR3 alterations.

A New Hope for Men with Metastatic Prostate Cancer

The Research Institute of McGill University Health Centre (RI-MUHC) has initiated a global Phase 1 clinical trial for Actinium-225, a novel treatment targeting metastatic prostate cancer. This trial, led by Dr. Ramy Saleh, aims to evaluate the safety and tolerability of Actinium-225, which targets the prostate-specific membrane antigen (PSMA) to kill cancer cells while sparing healthy organs. The study represents a significant advancement in precision medicine for patients who have exhausted other treatment options.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy